Development of adjuvant nanocarrier systems for seasonal influenza A (H3N2) vaccine based on Astragaloside VII and gum tragacanth (APS) |
| |
| Institution: | 1. Izmir Institute of Technology, Faculty of Engineering, Department of Bioengineering, 35433 Gülbahçe, Urla, Izmir, Turkey;2. Mersin University, Faculty of Engineering, Department of Chemical Engineering, 33343 Mersin, Turkey;3. Bornova Veterinary Control and Research Institute, 35100 Bornova, Izmir, Turkey;4. Ege University, Faculty of Engineering, Department of Bioengineering, 35100 Bornova, Izmir, Turkey;1. Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden;2. Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden;3. Paediatric Rheumatology Unit, Astrid Lindgren Children’s Hospital, Stockholm, Sweden;4. National Reference Center for Influenza, Division of Influenza and Other Respiratory Viruses, Robert Koch Institut, Berlin, Germany;5. Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden;1. São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil;2. São Paulo State University (UNESP), School of Dentistry, Department of Physiology & Pathology, Araraquara, SP, Brazil;1. Department of Pharmaceutical Botany, Faculty of Pharmacy, Ege University, Bornova, İzmir, 35030, Turkey;2. Department of Pharmacology, College of Veterinary Medicine, Cairo University, Giza 12211, Egypt;3. Department of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942 Al-Kharj, Saudi Arabia;4. Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942 Al-Kharj, Saudi Arabia;5. Department of Bioengineering, Faculty of Engineering, Izmir Institute of Technology, 35430 Urla, İzmir, Turkey |
| |
| Abstract: | Adjuvants are chemical/biological substances that are used in vaccines to increase the immunogenicity of antigens. A few adjuvants have been developed for use in human vaccines because of their limitations including lack of efficacy, unacceptable local or systemic toxicity, the difficulty of manufacturing, poor stability, and high cost. For that reasons, novel adjuvants/adjuvant systems are under search. Astragaloside VII (AST-VII), isolated from Astragalus trojanus, exhibited significant cellular and humoral immune responses. The polysaccharides (APS) obtained from the roots of Astragalus species have been used in traditional Chinese medicine and possess strong immunomodulatory properties. In the present study, the immunomodulatory effects of a newly developed nanocarrier system (APNS: APS containing carrier) and its AST-VII containing formulation (ANS: AST-VII + APNS), on seasonal influenza A (H3N2) vaccine were investigated. Inactivated H3N2 alone or its combinations with test compounds/formulations were intramuscularly injected into Swiss albino mice. Four weeks after immunization, the immune responses were evaluated in terms of antibody and cytokine responses as well as splenocyte proliferation. APNS demonstrated Th2 mediated response by increasing IgG1 antibody titers, whereas ANS showed response towards Th1/Th2 balance and Th17 by producing of IFN-γ, IL-17A and IgG2a. Based on these results, we propose that APNS and ANS are good candidates to be utilized in seasonal influenza A vaccines as adjuvants/carrier systems. |
| |
| Keywords: | Gum tragacanth Astragaloside VII Adjuvant Nanocarrier Influenza |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
